Non-Hodgkin Lymphoma With an Atypical Presentation: A Solitary Paravertebral Mass on FDG PET/CT
An 81-year-old woman was admitted with chest tightness and shortness of breath. Chest CT revealed massive pleural effusion on the right side as well as a right paravertebral soft tissue mass at the T8 to T10 level, showing intense enhancement. Her symptoms were successfully relieved by thoracentesis catheter drainage. On PET/CT, the paravertebral lesion demonstrated increased FDG uptake with an SUVmax of 7.5, indicating a suspected diagnosis of malignancy. Eventually, a CT-guided needle biopsy was performed, which confirmed the diagnosis of non-Hodgkin lymphoma.
CONCLUSIONS: SS-associated T cell lymphomas constitute a minority. Treatment with anti-CD20 monoclonal antibody (mAb) and viral infections may be implicated in their pathogenesis. PMID: 33025901 [PubMed - as supplied by publisher]
(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model.
ConclusionViable-Targeting US-CNB was superior to routine US-CNB in term of the yield of actionable diagnosis for deep-sited dominant lesions suspicious of lymphoma, which demonstrated a potential to be the initial approach in this setting.
(University of Arizona Health Sciences) Skipping radiation and receiving less chemotherapy may become the new standard of care for some lymphoma patients, according to a recent collaborative University of Arizona Health Sciences-led study. Published in the Journal of Clinical Oncology, the study suggests using a positron emission tomography (PET) scan after three cycles of a combination of chemotherapy drugs known as R-CHOP. If the patient's scan is negative, they can proceed with another round of R-CHOP to complete their treatment.
CONCLUSIONS: Our findings extended evidence for TFA intake and DLBCL risk but not for other NHL subtypes. Reduced TFA consumption through dietary choices or health policy measures may support prevention of DLBCL, an aggressive NHL subtype. PMID: 33022699 [PubMed - as supplied by publisher]
AbstractPurposeThe majority of childhood, adolescent, and young adult cancer survivors (CAYACS) are at risk of late effects but may not receive long-term follow-up care for these. Here, we investigated (1) self-reported late effects, (2) long-term follow-up care, and (3) factors associated with receiving follow-up care in a population-based sample of Norwegian long-term CAYACS.MethodsSurvivors were identified by the Cancer Registry of Norway. All> 5-year survivors diagnosed between 1985 and 2009 with childhood cancer (CCS, 0 –18 years old, excluding CNS), breast cancer (BC, stages I–III), colorectal cancer (...
ConclusionsPatients with diffuse large B-cell lymphoma have an aggressive clinical course, but cardiac involvement is very rare. In our patient ’s case, pericardial involvement was observed after treatment and scanning revealed that recurrence took place in an area different from the pericardium. Cooperation of clinicians and pathologists and rapid evaluation are very important in cases of diffuse large B-cell lymphoma relapse. Although a tumoral invasion of the pericardium mostly suggests secondary malignancies, it should be kept in mind that recurrence of lymphoma is also possible.
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Deanna Blansky, Ioannis Mantzaris, Thomas Rohan, H. Dean Hosgood
Publication date: December 2020Source: Microchemical Journal, Volume 159Author(s): Alessandra de Sousa Mesquita, Hans Rolando Zamora-Obando, Fábio Neves dos Santos, Jayr Schmidt-Filho, Vladmir Cordeiro de Lima, Felipe D'Almeida Costa, Victor Piana de Andrade, Marcos Nogueira Eberlin, Ana Valéria Colnaghi Simionato
(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia.